Table 3.
Univariate and multivariate OS and PFS analysis
| Parameters | Test variables | Univariate analysis | Multivariate analysis | ||||
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| OS | |||||||
| Drug clearance | Q4 vs. Q3 vs. Q2 vs. Q1 | 1.61 | 1.26 to 2.05 | <0.001* | 1.58 | 1.20 to 2.08 | 0.001* |
| Tumor type |
NSCLC vs. other | 1.07 | 0.61 to 1.88 | 0.80 | 0.79 | 0.29 to 2.14 | 0.64 |
| Melanoma vs. other | 0.48 | 0.28 to 0.85 | 0.01* | 0.53 | 0.20 to 1.40 | 0.19 | |
| MPM vs. other | 2.24 | 1.09 to 4.61 | 0.03* | 2.59 | 0.83 to 8.09 | 0.10 | |
| UCC vs. other† | 1.95 | 0.98 to 3.88 | 0.06 | ||||
| Prior treatment | 2 vs. 1 vs. none | 1.85 | 1.27 to 2.69 | 0.001* | 1.24 | 0.75 to 2.06 | 0.39 |
| Age (years) | Continuous | 0.998 | 0.98 to 1.02 | 0.87 | |||
| Gender | Male vs. female | 1.05 | 0.60 to 1.82 | 0.87 | |||
| WHO | 2 vs. 1 vs. 0 | 1.43 | 0.94 to 2.16 | 0.09 | 0.99 | 0.57 to 1.73 | 0.98 |
| Smoking | Never vs. current/former | 0.72 | 0.29 to 1.83 | 0.49 | |||
| LDH (U/L) | Continuous | 1.001 | 1.000 to 1.002 | 0.005* | 1.002 | 1.001 to 1.003 | 0.002* |
| PFS | |||||||
| Drug clearance | Q4 vs. Q3 vs. Q2 vs. Q1 | 1.51 | 1.15 to 1.98 | 0.003* | 1.56 | 1.17 to 2.07 | 0.002* |
| Tumor type | NSCLC vs. melanoma | 1.28 | 0.72 to 2.29 | 0.39 | |||
| Prior treatment | 2 vs. 1 vs. none | 1.59 | 1.02 to 2.46 | 0.04* | 1.29 | 0.81 to 2.08 | 0.29 |
| Age (years) | Continuous | 0.99 | 0.97 to 1.02 | 0.50 | |||
| Gender | Male vs. female | 1.07 | 0.59 to 1.96 | 0.82 | |||
| WHO | 2 vs. 1 vs. 0 | 1.08 | 0.70 to 1.67 | 0.73 | |||
| Smoking | Never vs. current/former | 1.65 | 0.77 to 3.54 | 0.20 | |||
| LDH (U/L) | Continuous | 1.002 | 1.000 to 1.002 | <0.001* | 1.002 | 1.001 to 1.003 | <0.001* |
Table showing the results of the univariate and multivariate Cox regression survival analysis for OS and PFS. Tumor type (NSCLC, melanoma, MPM and UCC) integrated as a test variable and contrasted to all other patients in the dataset, to allow for correction of tumor type in the multivariate analysis. Parameters (including individual drug clearance and known prognostic factors) with a p<0.10 are incorporated in the multivariate analysis. The HR is shown, with the 95% CI and the p value (p).
*Significance (p<0.05).
†Not computed in the multivariate analysis, linearly dependent on other test variables for the parameter.
LDH, lactate dehydrogenase; LDH, lactate dehydrogenase; MPM, malignant pleural mesothelioma; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; UCC, urothelial cell carcinoma.